Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Triple Negative Breast Neoplasms × Erythrocyte Count × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Carboplatin 6 Gemcitabine 4 130-nm albumin-bound paclitaxel 3 Paclitaxel 2 olaparib 1 eryaspase 1 camrelizumab 1 Erythrocyte Count 1 Epirubicin 1 Doxorubicin 1 Docetaxel 1 Cyclophosphamide 1 Cisplatin 1 Capecitabine 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03674242 2022-08-01

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)

ERYtech Pharma

Phase 2/3 Terminated

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡